

1 **TITLE:** Reproducible and Transparent Research Practices in Published Neurology Research

2 **Authors:** Shelby Rauh, MS¹, Trevor Torgerson, BS¹, Austin L. Johnson, BS¹, Jonathan Pollard, BS²,
3 Daniel Sylvester Tritz, BS¹, Matt Vassar, PhD¹.

4 **Affiliation:**

5 1. Oklahoma State University Center for Health Sciences, Tulsa, Oklahoma.

6 2. Kansas City University of Medicine and Biosciences, Kansas City, Missouri.

7 **Corresponding Author:** Shelby Rauh 1111 W 17th St. Tulsa, OK 74137.

8 Email: shelby.rauh@okstate.edu

9 Phone: (918) 582-1972

10 **Data Availability Statement:** All protocols, materials, and raw data are available online.

11 **Funding and Conflict of Interest:** This study was funded through the 2019 Presidential Research

12 Fellowship Mentor – Mentee Program at Oklahoma State University Center for Health Sciences. We

13 declare no conflicts of interest.

14

15 **Abstract**

16 *Background*

17 The objective of this study was to evaluate the nature and extent of reproducible and transparent research
18 practices in neurology research.

19 *Methods*

20 The NLM catalog was used to identify MEDLINE-indexed neurology journals. A PubMed search of these
21 journals was conducted to retrieve publications over a 5-year period from 2014 to 2018. A random sample
22 of publications was extracted. Two authors conducted data extraction in a blinded, duplicate fashion using
23 a pilot-tested Google form. This form prompted data extractors to determine whether publications
24 provided access to items such as study materials, raw data, analysis scripts, and protocols. In addition, we
25 determined if the publication was included in a replication study or systematic review, was preregistered,
26 had a conflict of interest declaration, specified funding sources, and was open access.

27 *Results*

28 Our search identified 223,932 publications meeting the inclusion criteria, from which 300 were randomly
29 sampled. Only 290 articles were accessible, yielding 202 publications with empirical data for analysis.
30 Our results indicate that 8.99% provided access to materials, 9.41% provided access to raw data, 0.50%
31 provided access to the analysis scripts, 0.99% linked the protocol, and 3.47% were preregistered. A third
32 of sampled publications lacked funding or conflict of interest statements. No publications from our
33 sample were included in replication studies, but a fifth were cited in a systematic review or meta-analysis.

34 *Conclusions*

35 Current research in the field of neurology does not consistently provide information needed for
36 reproducibility. The implications of poor research reporting can both affect patient care and increase
37 research waste. Collaborative intervention by authors, peer reviewers, journals, and funding sources is
38 needed to mitigate this problem.

39 **Introduction**

40 Scientific advancement is hampered by potential research flaws, such as the lack of replication; poor
41 reporting; selective reporting bias; low statistical power; and inadequate access to materials, protocols,
42 analysis scripts, and experimental data.[1–3] These factors may undermine the rigor and reproducibility
43 of published research. Substantial evidence suggests that a large proportion of scientific evidence may be
44 false, unreliable, or irreproducible.[4–8] Estimates of irreproducible research range from 50% to 90% in
45 preclinical sciences[9] and substantiated in a recent survey of scientists. Prior survey studies reported that
46 roughly 70% of scientists were unable to replicate another scientist's experiment, and 90% agreed that
47 scientific research is currently experiencing a “reproducibility crisis.”[7]

48
49 Reproducibility is vital for scientific advancement as it aids in enhancing the credibility of novel scientific
50 discoveries and mitigates erroneous findings. One review discussed potential pitfalls in fMRI
51 reproducibility, such as scanner settings, consistency of cognitive tasks, and analysis methods.[10] Boekel
52 et al. replicated five fMRI studies measuring a total of 17 structural brain-behavior correlations. After
53 reanalysis, only one of the 17 was successfully replicated.[11] Thus, practices related to transparency and
54 reproducibility can be improved within fMRI and other neurology research.

55
56 Adopting open science in neurology would help mitigate irreproducible research, such as the studies on
57 brain-behavior correlation. Open science practices – such as data sharing, open access articles, sharing
58 protocols and methods, and study preregistration – promote transparency and reproducibility.[12] For
59 example, preregistering a study helps guard against selective outcome reporting.[13] Selective outcome
60 reporting occurs when discrepancies exist between outcome measures prespecified in trial registries or
61 research protocols and the outcomes listed in the published report.[14] In neurology, an audit of
62 randomized clinical trials published in neurology journals found 180 outcome inconsistencies across 180
63 trials, with most inconsistencies favoring changes in accordance with statistically significant results.
64 Additionally, only 55% of neurology trials were prospectively registered[15], providing indications that

65 neurology researchers are not adhering to transparency and reproducibility practices early in research
66 planning. Reproducible research and open science practices are widely endorsed by a large proportion of
67 authors. Despite this support, evidence suggests that authors infrequently implement them.[16–18]

68
69 Given the recent attention to the reproducibility crisis in science, further investigation is warranted to
70 ensure the existence of reproducible and transparent research in the field of neurology. Here, we examine
71 key transparency- and reproducibility-related research practices in the published neurology literature. Our
72 findings from this investigation may serve as a baseline to measure future progress regarding transparency
73 and reproducibility-related practices.

74

75 **Methods**

76 This observational, cross-sectional study used the methodology proposed by Hardwicke et. al.[3], with
77 modifications. We reported this study in accordance with the guidelines for meta-epidemiological
78 methodology research[19] and, when pertinent, the Preferred Reporting Items for Systematic Reviews and
79 Meta-Analyses (PRISMA).[20] Our study did not use any human subjects or patient data and, as such,
80 was not required to be approved by an institutional review board prior to initiation. We have used The
81 Open Science Framework to host our protocol, materials, training video, and study data in a publically
82 available database (<https://osf.io/n4yh5/>).

83

84 *Journal and Publication Selection*

85 On June 25, 2019, one investigator (D.T.) searched the National Library of Medicine (NLM) catalog for
86 all journals using the subject terms tag “Neurology[ST].” The inclusion criteria required that all journals
87 publish English, full-text manuscripts and be indexed in the MEDLINE database. The final list of
88 included journals was created by extracting the electronic international standard serial number (ISSN) or
89 the linking ISSN, if necessary. PubMed was searched with the list of journal ISSNs on June 25, 2019 to
90 identify all publications. We then limited our publication sample to those between January 1, 2014 and

91 December 31, 2018. Three hundred publications within the time period were randomly sampled for data
92 extraction. The rest were available, but not needed (<https://osf.io/wvkgc/>).

93

94 *Extraction Training*

95 Prior to data extraction, two investigators (S.R. and J.P.) completed in-person training designed and led
96 by another investigator (D.T.). The training sessions included reviewing the protocol, study design, data
97 extraction form, and likely locations of necessary information within example publications. The two
98 authors being trained received two sample publications to extract data from. This example data extraction
99 was performed in the same duplicate and blinded fashion used for data acquisition for this study. The two
100 investigators then met to reconcile any discrepancies. After the two sample publications were completed,
101 investigators extracted data and reconciled differences from the first 10 of the included 300 neurology
102 publications. This process insured interrater reliability prior to analyzing the remaining 290 publications.
103 A final reconciliation meeting was conducted, with a third investigator (D.T.) available for disputes but
104 not needed.

105

106 *Data Extraction*

107 After completing training, the same two investigators extracted data from the included list of randomly
108 sampled publications between June 3, 2019 and June 10, 2019 using a pilot-tested Google form. This
109 Google form was based on the one used by Hardwicke et al., but including modifications.[3] We specified
110 the 5-year impact factor and that for the most recent year as opposed to the impact factor of a specific
111 year. The available types of study designs were expanded to include case series, cohort studies, secondary
112 analyses, chart reviews, and cross-sectional analyses. Last, we specified funding sources, such as hospital,
113 private/industry, non-profit, university, or mixed, instead of restricting the criteria to public or private.

114

115 *Assessment of Reproducibility and Transparency Characteristics*

116 This study used the methodology by Hardwicke et al.[3] for analyses of transparency and reproducibility
117 of research, with modifications. Full publications were examined for funding disclosures, conflicts of
118 interest, available materials, data, protocols, and analysis scripts. Publications were coded to fit two
119 criteria: those with and those without empirical data. Publications without empirical data (e.g., editorials,
120 reviews, news, simulations, or commentaries without reanalysis) were analyzed for conflict of interest
121 statements, open access, and funding. Given that protocols, data sets, and reproducibility were not
122 relevant, these were omitted. Case studies and case series were listed as empirical studies; however,
123 questions pertaining to the availability of materials, data, protocol, and registration were excluded due to
124 previous study recommendations.[18] Data extraction criteria for each study design is outlined in Table 1.

125

126 *Publication Citations Included in Research Synthesis and Replication*

127 For both empirical and nonempirical studies, we measured the impact factor of each journal by searching
128 for the publication title on the Web of Science (<https://webofknowledge.com>). For empirical studies, we
129 used the Web of Science to determine whether our sample of studies were cited in either a meta-analysis,
130 systematic review, or a replication study. The Web of Science provided access to studies that cited the
131 queried publication and provided the title, abstract, and link to the full-text article. This permitted
132 evaluation of the inclusion of the queried article in data synthesis. Extraction was performed by both
133 investigators in a duplicate, blinded fashion.

134

135 *Assessment of Open Access*

136 Important core components of publications necessary for reproducibility are only available within the full
137 text of a manuscript. To determine the public's access to each publication's full text, we systematically
138 searched the Open Access Button (<https://openaccessbutton.org>), Google, and PubMed. First, we searched
139 the title and DOI using the Open Access Button to determine if the publication was available for public
140 access. If this search returned no results or had an error, then we searched the publication title on Google

141 or PubMed and reviewed the journal website to determine if the publication was available without a
142 paywall.

143

144 *Statistical Analysis*

145 Microsoft Excel was used to report statistics for each category of our analysis. In particular, we used
146 Excel functions to calculate our study characteristics, results, and 95% confidence intervals.

147

148 **Results**

149 *Journal and Publication Selection*

150 After searching the National Library of Medicine catalog, 490 neurology journals were eligible for
151 analysis. After screening for inclusion criteria, 299 journals remained for analysis, yielding 223,932
152 publications. Of the 223,932 publications, we randomly sampled 300 (<https://osf.io/qfy7u/>). Ten
153 publications were inaccessible, which left 290 publications for analysis. Of the 290 eligible publications,
154 218 provided analyzable empirical data, and 72 articles were excluded because they did not contain
155 characteristics measurable for reproducibility. Of the 218 publications eligible for analysis, an additional
156 16 case studies and case series were excluded, as they are irreproducible. Our final analysis was based on
157 202 publications with measurable reproducibility characteristics (Figure 1 and Table 1).

158

159 *Sample Characteristics*

160 Of the eligible publications, the median 5-year impact factor was 3.555 (Interquartile range (IQR): 2.421-
161 4.745), although 20 publications had inaccessible impact factors. The United States was the location of
162 most of the primary authors (30.69%, 89/290) and the country of most publications (56.55%, 164/290).
163 Of the 290 publications that were accessible, 33.10% did not report a funding source (96/290), and
164 27.93% reported funding from mixed sources (81/290; Table 2).

165

166 Of the randomly sampled 300 publications that were findable, 61.38% were not accessible to the public
167 without a paywall (178/290), and only 40.34% were available to the public via the Open Access Button
168 (117/290). Approximately half of analyzed publications stated that they did not have any conflicts of
169 interest (53.10%, 154/290), and 33.10% did not report whether or not conflicts of interest existed
170 (96/290). Humans were the focus of 51.72% of the analyzed publications (150/290). Additional sample
171 characteristics are viewable in Supplemental Tables 1, 2, and 3.

172

173 *Reproducibility-Related Characteristics*

174 Among the 202 publications with empirical data that were analyzed, a mere 3.47% provided
175 preregistration statements or claimed to be preregistered (7/202). Of the 202 publications, just 0.99%
176 provided access to the protocol (2/202). Interestingly, only 8.99% provided access to the materials list
177 (17/189), 9.41% provided access to the raw data (19/202), and just a single article provided the analysis
178 script (0.50%, 1/202). Not a single publication claimed to be a replication study. Additional
179 characteristics are viewable in Supplemental Tables 1, 2, and 3.

180

181 **Discussion**

182 Our analysis demonstrates inadequate reproducibility practices within neurology and neuroscience
183 research. We found that few publications contained data or materials availability statements and even
184 fewer contained a preregistration statement, made the protocol available, or included an analysis script.
185 Our overall finding – that a majority of neurology publications lack the information necessary to be
186 reproduced and transparent – is comparable to findings in the social and preclinical sciences.[3, 5, 21–24]
187 Here, we present a discussion on prominent reproducibility and transparency indicators that were lacking
188 in our study while presenting recommendations and practices to help improve neurology research.

189

190 First, data and materials availability is essential for reproducing research. Without source data,
191 corroborating the results is nearly impossible. Without a detailed description of materials, conducting the

192 experiment becomes a guessing game. Less than 10% of publications in our sample reported either a data
193 or a materials availability statement. Efforts toward data sharing in neurological research originated with
194 brain mapping and neuroimaging, but has spread to other areas within the specialty to improve
195 reproducibility, transparency, and data aggregation.[25] Although data sharing poses challenges, steps
196 have been taken in fMRI studies.[26, 27] fMRI data are complex and cumbersome to handle, but can be
197 managed with software, such as Automatic Analysis[28], C-BRAIN[29], and NeuroImaging Analysis
198 Kit.[30] Furthermore, these data can be hosted on online repositories, such as The National Institute of
199 Mental Health Data Archive[31], Figshare[32], and other National Institutes of Health repositories.[33]
200 Although researchers may take these steps voluntarily, journals – the final arbiters of research
201 publications – can require such practices. Our study found that less than half of the sampled journals had
202 a data availability policies, with approximately 20% of articles from these journals reporting source
203 data.[34] Another study in *PLOS ONE* found that only 20% of nearly 50,000 publications included a data
204 sharing statement and found that once a data sharing policy was enacted, open access to raw data
205 increased.[35] Based on this evidence, journals and funders should consider implementing and enforcing
206 data sharing policies that, at minimum, require a statement detailing whether data are available and where
207 data are located. For example, the journal *Neurology* has endorsed the International Committee of
208 Medical Journal Editors policy of requiring a data sharing statement and encourages open access.[36–38]
209 If other neurology journals follow suit, an environment of transparency and reproducibility may be
210 established.

211
212 Second, preregistration practices were uncommon among neurology researchers. Preregistration prior to
213 conducting an experiment safeguards against selective outcome reporting. This form of bias affects the
214 quality of research in neurology. For example, when a randomized controlled trial (RCT) contains an
215 outcome deemed “not significant” and is selectively removed from a trial, the validity of the RCT may be
216 questioned. Previous studies have already established outcome reporting bias as an issue within
217 neurology, noting that only 40% of analyzed RCTs were preregistered and, therefore, prespecified their

218 analysis.[15] This same study found outcome reporting inconsistencies that often favored statistically
219 significant results.[15] *JAMA Neurology*, *The Lancet Neurology*, and *Neurology* all requiring the
220 preregistration of clinical trials prior to study commencement in accordance with the International
221 Committee of Medical Journal Editors (ICJME).[39] Only *The Lancet Neurology* mentions registration of
222 other study designs, such as observational studies, and only “encourages the registration of all
223 observational studies on a WHO-compliant registry.”[40–42] The ICJME notes that although non-trial
224 study designs lack a researcher prespecified intervention, it is recommended to preregister all study types
225 to discourage selective reporting and selective publication of results [39]. On ClinicalTrials.gov alone,
226 almost 65,000 observational study designs have been preregistered, comprising 21% of all registered
227 studies [43]. Encouraging the preregistration of clinical trials and observational studies, alike, will
228 increase transparency, increase the evidence available for systematic reviews and meta-analyses, and
229 improve reproducibility [44, 45].

230

231 *Moving Forward*

232 We propose the following solutions to promote reproducible and transparent research practices in
233 neurology. With regards to journals, we recommend requiring open data sharing upon submission, or, at
234 least, a statement from the authors signifying why open data sharing does not apply to their study. There
235 are many open data repositories available, including the Open Science Framework (<https://osf.io/>),
236 opendatarepository.org, and others listed at re3data.org. Second, we recommend journals and funding
237 providers consider incentivizing reproducible research practices. For example, the Open Science
238 Framework awards “badges” for open research practices, such as open data sharing, materials availability,
239 and preregistration.[46] If one or more of these reproducible research practices do not apply to a
240 particular study, a statement as to such should still qualify for the award. One Neuroscience journal,
241 *Journal of Neurochemistry*, has already implemented open science badges with considerable success.[47]
242 With regards to researchers, better awareness and education is necessary to encourage transparent and
243 reproducible practices. Organizations, such as the *Global Biological Standards Institute*, have committed

244 to improving the reproducibility of life sciences research through multiple methods, including training
245 and educating researchers in effective trial design.[48, 49] The institute's president has called for and
246 implemented training programs aimed at teaching students, postdoctoral fellows, and principal
247 investigators the importance of robust study design.[48] Additionally, we propose that medical schools
248 and residency programs incorporate classes and didactic programs detailing proper experimental design
249 with an emphasis on reproducible scientific practices. Research education should be a pillar of medical
250 education, as physicians play an important role in guiding evidence-based healthcare. We anticipate that
251 these recommendations, if implemented, will improve reproducibility within neurology and, as a result,
252 the quality of research produced within this specialty.

253

254 *Strengths and Limitations*

255 We feel that our methodology is robust and has many strengths, including blind and duplicate data
256 extraction. Additionally, our protocol and data are available online to encourage reproducibility and
257 transparency. However, we acknowledge a few limitations. First, we recognize that not all publications
258 (clinical trials and protected patient data) are readily able to share their data and materials, although we
259 feel a statement should still be reported. Second, we did not contact authors to obtain data, materials or
260 analysis scripts and only used published materials for extraction. Had we contacted the authors, then
261 source data, materials, and protocols may have been available.

262

263 *Conclusion*

264 In summary, improvement is needed to incorporate reproducibility factors in neurology research. Such
265 necessary improvement is attainable. Authors, journals, and peer-reviewers all have a part to play in
266 developing an improved community of patient-centered neurology researchers. Reproducibility is
267 paramount in evidence-based medicine to corroborate findings and ensure physicians have the highest
268 quality evidence upon which to base patient care.

269

270 **Resources:**

- 271 1. Wicherts JM, Borsboom D, Kats J, Molenaar D. The poor availability of psychological research data
272 for reanalysis. *Am Psychol.* 2006;61:726–8.
- 273 2. Iqbal SA, Wallach JD, Khoury MJ, Schully SD, Ioannidis JPA. Reproducible Research Practices and
274 Transparency across the Biomedical Literature. *PLoS Biol.* 2016;14:e1002333.
- 275 3. Hardwicke TE, Wallach JD, Kidwell M, Ioannidis J. An empirical assessment of transparency and
276 reproducibility-related research practices in the social sciences (2014-2017). 2019.
277 doi:10.31222/osf.io/6uhg5.
- 278 4. Ioannidis JPA. Why most published research findings are false. *PLoS Med.* 2005;2:e124.
- 279 5. Button KS, Ioannidis JPA, Mokrysz C, Nosek BA, Flint J, Robinson ESJ, et al. Power failure: why
280 small sample size undermines the reliability of neuroscience. *Nat Rev Neurosci.* 2013;14:365–76.
- 281 6. Peng R. The reproducibility crisis in science: A statistical counterattack. *Significance.* 2015;12:30–2.
- 282 7. Baker M. 1,500 scientists lift the lid on reproducibility. *Nature.* 2016;533:452–4.
- 283 8. Begley CG, Glenn Begley C, Ioannidis JPA. Reproducibility in Science. *Circulation Research.*
284 2015;116:116–26. doi:10.1161/circresaha.114.303819.
- 285 9. Freedman LP, Cockburn IM, Simcoe TS. The Economics of Reproducibility in Preclinical Research.
286 *PLoS Biol.* 2015;13:e1002165.
- 287 10. Bennett CM, Miller MB. How reliable are the results from functional magnetic resonance imaging?
288 *Ann N Y Acad Sci.* 2010;1191:133–55.
- 289 11. Boekel W, Wagenmakers E-J, Belay L, Verhagen J, Brown S, Forstmann BU. A purely confirmatory
290 replication study of structural brain-behavior correlations. *Cortex.* 2015;66:115–33.

- 291 12. Banks GC, Field JG, Oswald FL, O'Boyle EH, Landis RS, Rupp DE, et al. Answers to 18 Questions
292 About Open Science Practices. *J Bus Psychol.* 2019;34:257–70.
- 293 13. Nosek BA, Ebersole CR, DeHaven AC, Mellor DT. The preregistration revolution. *Proc Natl Acad*
294 *Sci U S A.* 2018;115:2600–6.
- 295 14. Mathieu S, Boutron I, Moher D, Altman DG, Ravaud P. Comparison of registered and published
296 primary outcomes in randomized controlled trials. *JAMA.* 2009;302:977–84.
- 297 15. Howard B, Scott JT, Blubaugh M, Roepke B, Scheckel C, Vassar M. Systematic review: Outcome
298 reporting bias is a problem in high impact factor neurology journals. *PLoS One.* 2017;12:e0180986.
- 299 16. Harris JK, Johnson KJ, Carothers BJ, Combs TB, Luke DA, Wang X. Use of reproducible research
300 practices in public health: A survey of public health analysts. *PLoS One.* 2018;13:e0202447.
- 301 17. Stuppel A, Singerman D, Celi LA. The reproducibility crisis in the age of digital medicine. *npj Digital*
302 *Medicine.* 2019;2:2.
- 303 18. Wallach JD, Boyack KW, Ioannidis JPA. Reproducible research practices, transparency, and open
304 access data in the biomedical literature, 2015–2017. *PLoS Biol.* 2018;16:e2006930.
- 305 19. Murad MH, Wang Z. Guidelines for reporting meta-epidemiological methodology research. *Evid*
306 *Based Med.* 2017;22:139–42.
- 307 20. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA
308 statement for reporting systematic reviews and meta-analyses of studies that evaluate health care
309 interventions: explanation and elaboration. *J Clin Epidemiol.* 2009;62:e1–34.
- 310 21. Prinz F, Schlange T, Asadullah K. Believe it or not: how much can we rely on published data on
311 potential drug targets? *Nat Rev Drug Discov.* 2011;10:712.

- 312 22. Begley CG, Glenn Begley C, Ellis LM. Raise standards for preclinical cancer research. *Nature*.
313 2012;483:531–3. doi:10.1038/483531a.
- 314 23. Tsilidis KK, Panagiotou OA, Sena ES, Aretouli E, Evangelou E, Howells DW, et al. Evaluation of
315 excess significance bias in animal studies of neurological diseases. *PLoS Biol*. 2013;11:e1001609.
- 316 24. Begley CG, Ioannidis JPA. Reproducibility in science: improving the standard for basic and
317 preclinical research. *Circ Res*. 2015;116:116–26.
- 318 25. Ferguson AR, Nielson JL, Cragin MH, Bandrowski AE, Martone ME. Big data from small data: data-
319 sharing in the “long tail” of neuroscience. *Nature Neuroscience*. 2014;17:1442–7. doi:10.1038/nn.3838.
- 320 26. Nichols TE, Das S, Eickhoff SB, Evans AC, Glatard T, Hanke M, et al. Best practices in data analysis
321 and sharing in neuroimaging using MRI. *Nat Neurosci*. 2017;20:299–303.
- 322 27. Borghi JA, Van Gulick AE. Data management and sharing in neuroimaging: Practices and perceptions
323 of MRI researchers. *PLoS One*. 2018;13:e0200562.
- 324 28. Cusack R, Vicente-Grabovetsky A, Mitchell DJ, Wild CJ, Auer T, Linke AC, et al. Automatic
325 analysis (aa): efficient neuroimaging workflows and parallel processing using Matlab and XML. *Front*
326 *Neuroinform*. 2014;8:90.
- 327 29. CBRAIN | Home. <http://www.cbrain.ca/>. Accessed 14 Aug 2019.
- 328 30. NITRC: NeuroImaging Analysis Kit (NIAK): Tool/Resource Info.
329 <https://www.nitrc.org/projects/niak>. Accessed 14 Aug 2019.
- 330 31. NDA. <https://nda.nih.gov/>. Accessed 14 Aug 2019.
- 331 32. Kraker P, Lex E, Gorraiz J, Gumpenberger C, Peters I. Research Data Explored II: the Anatomy and
332 Reception of figshare. arXiv [cs.DL]. 2015. <http://arxiv.org/abs/1503.01298>.

- 333 33. NIH Data Sharing Repositories. 2013.
334 https://www.nlm.nih.gov/NIHbmic/nih_data_sharing_repositories.html. Accessed 14 Aug 2019.
- 335 34. Johnson JN, Hanson KA, Jones CA, Grandhi R, Guerrero J, Rodriguez JS. Data Sharing in
336 Neurosurgery and Neurology Journals. *Cureus*. 2018;10:e2680.
- 337 35. Federer LM, Belter CW, Joubert DJ, Livinski A, Lu Y-L, Snyders LN, et al. Data sharing in PLOS
338 ONE: An analysis of Data Availability Statements. *PLoS One*. 2018;13:e0194768.
- 339 36. Taichman DB, Sahni P, Pinborg A, Peiperl L, Laine C, James A, et al. Data Sharing Statements for
340 Clinical Trials: A Requirement of the International Committee of Medical Journal Editors. *Ethiopian
341 journal of health sciences*. 2017;27:315–8.
- 342 37. Baskin PK, Gross RA. The new Neurology: Redesigns, short articles for print, full articles online, and
343 data availability policies. *Neurology*. 2017;89:2026–8.
- 344 38. Research Policies and Guidelines | American Academy of Neurology Journals.
345 <https://www.neurology.org/research-policies-and-guidelines>. Accessed 14 Aug 2019.
- 346 39. of Medical Journal Editors IC, Others. Recommendations for the conduct, reporting, editing, and
347 publication of scholarly work in medical journals. 2016.
- 348 40. Instructions for Authors | JAMA Neurology | JAMA Network.
349 <https://jamanetwork.com/journals/jamaneurology/pages/instructions-for-authors>. Accessed 15 Aug 2019.
- 350 41. Research Policies and Guidelines | American Academy of Neurology Journals.
351 <https://www.neurology.org/research-policies-and-guidelines>. Accessed 15 Aug 2019.
- 352 42. Information for Authors. *The Lancet Neurology*. [https://els-jbs-prod-
353 cdn.literatumonline.com/pb/assets/raw/Lancet/authors/tln-info-for-authors-1564564413020.pdf](https://els-jbs-prod-cdn.literatumonline.com/pb/assets/raw/Lancet/authors/tln-info-for-authors-1564564413020.pdf). Accessed
354 15 Aug 2019.

355 43. Trends, Charts, and Maps - ClinicalTrials.gov. <https://clinicaltrials.gov/ct2/resources/trends>. Accessed
356 15 Aug 2019.

357 44. Dal-Ré R, Ioannidis JP, Bracken MB, Buffler PA, Chan A-W, Franco EL, et al. Making prospective
358 registration of observational research a reality. *Sci Transl Med*. 2014;6:224cm1.

359 45. Ioannidis JPA. The importance of potential studies that have not existed and registration of
360 observational data sets. *JAMA*. 2012;308:575–6.

361 46. Blohowiak BB, Cohoon J, de-Wit L, Eich E, Farach FJ, Hasselman F, et al. Badges to acknowledge
362 open practices. 2013. <https://osf.io/tvyxz/wiki/home/>.


363 47. Jones J, More Content by. *Connecting Research with Results: Open Science Badges*. 2018.
364 [https://www.wiley.com/network/researchers/licensing-and-open-access/connecting-research-with-results-](https://www.wiley.com/network/researchers/licensing-and-open-access/connecting-research-with-results-open-science-badges)
365 [open-science-badges](https://www.wiley.com/network/researchers/licensing-and-open-access/connecting-research-with-results-open-science-badges). Accessed 19 Jul 2019.

366 48. One Way to Fix Reproducibility Problems: Train Scientists Better. *The Scientist Magazine*®.
367 [https://www.the-scientist.com/news-opinion/one-way-to-fix-reproducibility-problems-train-scientists-](https://www.the-scientist.com/news-opinion/one-way-to-fix-reproducibility-problems-train-scientists-better-30577)
368 [better-30577](https://www.the-scientist.com/news-opinion/one-way-to-fix-reproducibility-problems-train-scientists-better-30577). Accessed 19 Jul 2019.

369 49. Our Mission - Global Biological Standards Institute. Global Biological Standards Institute.
370 <https://www.gbsi.org/about/who-we-are/>. Accessed 14 Aug 2019.

371

372 **Figure 1: Flow Diagram of Included and Excluded Studies for the Reproducibility Analysis**



373

374 **Table 1: Reproducibility related characteristics. Variable numbers (N) are dependent upon study**
 375 **design. Full detailed protocol pertaining to our measured variables is available online**
 376 **(<https://osf.io/x24n3/>)**

377

<i>Indicators of Reproducibility Included in Present Study</i>		<i>Significance of measure variable for transparency and reproducibility.</i>
Publications		
All (N=300)	Publication accessibility (Is the publication open access to the general public or accessible through a paywall?)	The general public's ability to access scientific research may increase transparency of results and improve the ability for others to critically assess studies, potentially resulting in more replication studies
Funding		
Included studies (N=290)	Funding statement (Does the publication state their funding sources?)	Explicitly providing source of funding may help mitigate bias and potential conflicts of interest
Conflict of Interest		
Included studies (N=290)	Conflict of interest statement (Does the publication state whether or not the authors had a conflict of interest?)	Explicitly providing conflicts of interest may allow for full disclosure of factors that may promote bias in the study design or outcomes
Publication Citations		
Empirical studies†	Citations by a systematic review/meta-analysis (Has the publication been	Systematic reviews and meta-analyses evaluate and compare existing literature to assess for

(N=205)	cited by any type of data synthesis publication, and if so, was it explicitly excluded?)	patterns, strengths, and weaknesses of studies regarding a particular field or topic
Analysis Scripts		
Empirical studies‡ (N=202)	Availability statement (Does the publication state whether or not the analysis scripts are available?)	Providing access to the analysis script helps improve credibility by providing the replicators the opportunity to analyze raw data with the same analysis procedure
	Method of availability (Ex: Are the analysis scripts available upon request or in a supplement?)	
	Accessibility (Can you view, download, or otherwise access the analysis scripts?)	
Materials		
Empirical studies¶ (N=189)	Availability statement (Does the publication state whether or not the materials are available?)	Providing the materials list allows replicators to reproduce study using the same materials, promoting
	Method of availability (Ex: Are the materials available upon request or in a supplement?)	
	Accessibility (Can you view, download, or otherwise access the materials?)	

Pre-registration		
Empirical studies‡ (N=202)	Availability statement (Does the publication state whether or not it was pre-registered?)	Pre-registering studies may help mitigate potential bias and increase the overall validity and reliability of a study
	Method of availability (Where was the publication pre-registered?)	
	Accessibility (Can you view or otherwise access the registration?)	
	Components (What components of the publication were pre-registered?)	
Protocols		
Empirical studies‡ (N=202)	Availability statement (Does the publication state whether or not a protocol is available?)	Providing replicators access to protocols allows the for more accurate replication of the study, promoting credibility
	Components (What components are available in the protocol?)	
Raw Data		
Empirical studies‡ (N=202)	Availability statement (Does the publication state whether or not the raw data are available?)	Providing replicators with access to raw data can help reduce potential bias and increase validity and reliability
	Method of availability (Ex: Are the raw data available upon request or in a supplement?)	

	Accessibility (Can you view, download, or otherwise access the raw data?)	
	Components (Are all the necessary raw data to reproduce the study available?)	
	Clarity (Are the raw data documented clearly?)	

† 'Empirical studies' are publications that include empirical data such as: clinical trial, cohort, case series, case reports, case-control, secondary analysis, chart review, commentaries (with data analysis), laboratory, surveys, and cross-sectional designs.

‡ Empirical studies determined to be case reports or case series were excluded in regard to reproducibility related questions (materials, data, protocol, and registration were excluded) as recommended by Wallach et al.

¶ Empirical studies determined to be either case reports, case series, commentaries with analysis, meta-analysis or systematic review were excluded as they did not provide materials to fit the category.

379

Table 2: Characteristics of Included Publications			
Characteristics		Variables	
		N (%)	95% CI
Funding N=290	University	11 (3.79)	1.63-5.95%
	Hospital	1 (0.34)	0-1.01%
	Public	54 (18.62)	14.22-23.03%
	Private/Industry	15 (5.17)	2.67-7.68%
	Non-Profit	11 (3.79)	1.63-5.95%
	Mixed	81 (27.93)	28.89-30.53%
	No Statement Listed	96 (33.01)	27.78-38.43%
	No Funding Received	21 (7.24)	4.31-10.17%
 			
Type of Study N=290	No Empirical Data	72 (24.83)	19.94-29.72%
	Meta-Analysis	12 (4.14)	1.88-6.39%
	Commentary with Analysis	1 (0.34)	0-1.01%
	Cost-Effectiveness	1 (0.34)	0-1.01%
	Clinical Trial	26 (8.97)	5.73-12.20%
	Case Study	9 (3.10)	1.14-5.07%
	Case Series	7 (2.41)	0.68-4.15%
	Cohort	43 (14.83)	10.81-18.85%
	Chart Review	3 (1.03)	0-2.18%
	Case Control	9 (3.10)	1.14-5.07%
	Survey	5 (1.72)	0.25-3.20%
	Cross-Sectional	34 (11.72)	8.08-15.36%
	Secondary Analysis	2 (0.69)	0-1.63%

	Laboratory	65 (22.41)	17.69-27.13%
	Multiple Study Types	1 (0.34)	0-1.01%
5 Year Impact Factor N=278	Median	3.555	-
	1st Quartile	2.421	-
	3rd Quartile	4.745	-
	Interquartile Range	2.421-4.745	-

380

381

Supplemental 1: Additional Characteristics of Reproducibility in Neurology			
Studies			
Characteristics		Variables	
		N (%)	95% CI
Conflict of Interest Statement (N=290)	Statement, one or more conflicts of interest	40 (13.79)	9.89-17.70%
	Statement, no conflict of interest	154 (53.10)	47.46-58.75%
	No conflict of interest statement	96 (33.10)	27.78-38.43%
Data Availability (N=202)			
Data Availability (N=202)	Statement, some data are available	19 (9.41)	6.10-12.71%
	Statement, data are not available	0	0
	No data availability statement	183 (90.59)	87.29-93.90%
Material Availability (N=189)			
Material Availability (N=189)	Statement, some materials are available	17 (8.99)	5.76-12.23%
	Statement, materials are not available	0	0
	No materials availability statement	172 (91.01)	87.77-94.24%
Protocol Availability (N=202)			
Protocol Availability (N=202)	Full Protocol	2 (0.99)	0-2.11%
	No Protocol	200 (99.01)	97.89-100%
Analysis Scripts (N=202)			
Analysis Scripts (N=202)	Statement, some analysis scripts are available	1 (0.50)	0-1.29%
	Statement, analysis scripts are not available	0	0

	No analysis script availability statement	201 (99.50)	98.71-100%
Replication			
Studies (N=202)	Reports Replication Study	0	0
	No Clear Statement	202 (100)	100%
Open Access			
(N=290)	Yes - found via Open Access Button	117 (40.34)	34.79-45.90%
	Yes - found article via other means	5 (1.72)	0.25-3.20%
	Could not access through paywall	178 (61.38)	55.87-66.89%
Cited in a			
Systematic Review/ Meta-Analysis (a) (N=205)	No Citations	163 (79.51)	74.94-84.08%
	A Single Citation	28 (13.66)	9.77-17.54%
	One to Five Citations	13 (6.34)	3.58-9.10%
	More Than 5 Citations	1 (0.49)	0-1.28%
Abbreviations: CI, Confidence Interval. a - No studies were explicitly excluded from the systematic reviews or meta-analyses that cited the original article.			

383

Supplemental 2: Additional Characteristics of Reproducibility in Neurology			
Studies			
Characteristics		Variables	
		N (%)	95% CI
Pre-Registration (N=202)	Statement, says was pre--registered	7 (3.47)	1.40-5.54%
	Statement, says was not pre-registered	0	0
	No, there is no pre-registration statement	195 (96.53)	94.46-98.60%
Test Subjects (N=290)	Animals	51 (17.59)	13.28-21.89%
	Humans	150 (51.72)	46.07-57.38%
	Both	0	0
	Neither	89 (30.69)	25.47-35.91%
Country of Journal Publication (N=290)	United States	164 (56.55)	50.94-62.16%
	UK	69 (23.79)	18.97-28.61%
	Netherlands	24 (8.28)	5.16-11.39%
	Germany	6 (2.07)	0.46-3.68%
	Ireland	6 (2.07)	0.46-3.68%
	Switzerland	4 (1.38)	0.06-2.70%
	Taiwan	1 (0.34)	0-1.10%
	Other (a)	16 (5.52)	2.93-8.10%
Country of Corresponding	United States	89 (30.69)	25.47-35.91%
	China	20 (6.90)	4.03-9.76%

Author (N=290)	UK	19 (6.55)	3.75-9.35%
	Netherlands	5 (1.72)	0.25-3.20%
	Turkey	7 (2.41)	0.68-4.15%
	France	10 (3.45)	1.38-5.51%
	Canada	13 (4.48)	2.14-6.82%
	Italy	12 (4.14)	1.88-6.39%
	Brazil	7 (2.41)	0.68-4.15%
	Australia	17 (5.86)	3.20-8.52%
	Unclear	0	0
	Other	91 (31.38)	31.38-26.13%

384

Supplemental 3: Additional Characteristics of Reproducibility in Neurology Studies		
Characteristics		Variables
		N
Material Availability	Personal or institutional	0
	Supplementary information hosted by the journal	13
	Online third party	3
	Upon Request	1
	Yes, material was accessible	11
	No, material was not accessible	6
Data Availability	Personal or institutional	0
	Supplementary journal information	11
	Online third party	4
	Upon Request	4
	Other (b)	0
	Yes, data could be accessed and downloaded	4
	No, data count not be accessed and downloaded	15
	Yes, data files were clearly documented	1
	No, data files were not clearly documented	4
	Yes, data files contain all raw data	1
	No, data files do not contain all raw data	3
	Unclear if all raw data was available	0

Pre- Registration	Yes, there was a pre-regisration	7
	Registered on ClinicalTrials.Gov	4
	Registered on Other	3
	Hypothesis was pre-registered	2
	Methods were pre-registered	7
	Analysis plan was pre-registered	6

386